Member Info for mjdc500

I'm sure you'd be willing to put your money where your mouth is and upload share purchase receipts for all to see. If you truly felt it's a strong buy even at 40p then there'll be a receipt for that, as well.

+1, pault230.

I came to this chat board to see if the rampers were still shouting loudly now that price has gone "off the boil".

Can a case be made that this stock is worth buying, even at these levels? I have been in-and-out of this stock for years, and I can hardly think of another stock on any market where the board have beaten up their retail holders as this board has.

What reason is there to think that further dilution is unlikely, on any timescale?

It seems to me that any positive result from these initial trials is likely to present a good opportunity to get back whatever money we can, before the stock slides further.

They're very simple devices, to be honest.

A couple of temperature sensors, a battery, and a network connection.

Not much to go wrong, I'd have thought.

What on Earth happened at 1542 today? Two sells of 1.1M shares at 3.62p?

With a >5% spread, a 7% day-on-day increase is barely significant.

Whomever is selling these huge blocks of shares is stopping price from breaking out.

That's why it's important.

Who is responsible for the large sells that keep coming in around 39p? There was a 309k sell today around 2pm, almost wiping out today's buying.

I'd offer a contrary opinion to this thread but just can't press the keys in the right order.

My abject horror with Vlad's treatment of us PIs is reaching increasing heights in the past year or so.

+1, pault230.

The only reason anyone should ever buy shares is to eventually sell them. Nothing at all wrong with banking gains, particularly in a downtrend.

We got to a similar valuation in August '23, to be fair.

Smaller cap stocks tend to be driven on anticipation/speculation rather than fair value. It's true for all stocks IMO but much less so for mega-caps, not least because there are many more shareholders and in particular many more instos guiding the pricing of mega-caps.

Bottom line is there's little reason to think any stock is valued fairly, except with guidance of experts whom you trust, nor that a fair or unfair valuation means that purchasing that stock is a good or a bad investment.

My experience is that few people on this chat board are experts, nor are they very impartial; most are shareholders and are interested in seeing the recent rise resume, or at least sustain existing price, whether it's fair or not.

I have a lot of sympathy for the viewpoint that this stock is overvalued, at least for the moment.

Buying at this point, with the expectation of future profitability, and while the company is increasingly loss-making and heavily indebted, seems to me likely to create bagholders when the buyers inevitably become exhausted and the SP drops.

After all, selling volume has outweighed buying volume for quite a while, now.

At this point I'd be satisfied just getting my money back.

The slow bleed from 4p has left me 75% down on my investment.

My fault entirely for not showing any discipline and setting a stop, but this was bought a few years ago when it was oscillating between 5p and 10p. I thought my entry point represented good value!

Are we any the wiser as to when the suspension will be lifted?

Honestly, no. Reasons as follows.

The first is that I'm not their IP advisor. Ondo are already paying handsomely for a top-tier international firm to provide IP advice, and much as that advice is confidential between firm and Ondo, I am conflicted through being a shareholder.

The second thing is that if my opinion on it differs from the advice Ondo are receiving from said firm, then it could cause a furore. Plus, I don't think Craig would be very happy. And, justifiably so.

What I would say is the following.

All of the interaction between patent offices and the patent attorney is public record. You only have to consult the register which is directly linked from each national patent application.

How the claims have been amended is indicative of their relative strength in each jurisdiction. So, you can take a look at the granted claimset in (for example) the US, and see how it compares with the granted claimset in the UK. Look at what features have been included in the independent claims, and this tells you how much the claim scope has been narrowed. You can use this information to inform an understanding (however vague) regarding how easily the granted independent claims might be "worked around" by a competitor.

This is specifically the role that patent attorneys are paid for. I haven't looked closely enough at the amendments to say anything on this, in any case; I have merely noted that quite a few amendments to claim 1 were made, and that those amendments do differ between jurisdictions. Again, this is not very unusual.

It's also not particularly relevant to Ondo's commercial prospects, unless and until a competitor does come along. At that point, the question of infringement can be asked.

Some corrections.

WO2016110696A1 (https://worldwide.espacenet.com/patent/search?q=pn%3DWO2016110696A1) is the key document in their portfolio, not WO '834, which at least in Europe has been withdrawn. This is a PCT document which enables the priority GB national application to enter other national jurisdictions through the WIPO.

Amendments may be made during the international stage of examination, which in this case would be by an examiner in the European patent office in Munich or The Hague.

The national patent offices which then receive the international application may further insist on other amendments, to clarify and/or reduce the claim scope in order to make it patentable. This seems to have been quite extensive in GB, at least, and in other jurisdictions from a very cursive look; this is not very unusual for smaller companies with very specific inventions like this.

There is no EU patent. The UK is a signatory to the European Patent Convention which exists independently of the EU. Any European patent, if granted and which is then validated in the UK, is valid and enforceable patent in the UK. This can effectively extend protection beyond the typical 20 year period during which the earlier GB filing would be an active and enforceable patent.

@Bearsandbulls: that's a design, not a patent.

There's quite a lot of rudeness in many of these replies, so I'm not going to disclose or provide any analysis on what I've found, Craig having responded to my query to view their portfolio. Actually, unless you know the Applicant or Inventor name, it's far from trivial to simply search the entire global database of published art and expect to find anything at all.

Suffice to say, it's clear nobody here has any clue re: the significance of Ondo's portfolio, or where it's in force; almost all of the various comments made are completely, or substantially, wrong.

FWIW there is no such thing as a "global" patent. This is another reason I'd like to see their actual portfolio.

Where have these patents been recorded in RNS or online, please? I'd like to inspect them. I'm not surprised they have patents but I wasn't previously aware of them. FWIW I'm a patent attorney.

Does anyone have a reasonable idea when we can expect an announcement re: phase 1 trials for car-t?

I've seen estimates of Q3 which sound reasonable, but I'm looking for input from someone much more familiar with the early-stage pharma industry than me.

Trading low liquidity and/or AIM shares on T212 is a bad idea IMO. You are better off using a proper broker. You'll pay commission fees but they'll usually find you a better price if you're buying decent amounts, e.g. £1k, on both buys and sells. Def worth it.